In­ter­cept is de­nied full FDA ap­proval for Ocali­va, but claims it will keep drug on mar­ket

The FDA re­ject­ed the full ap­proval sub­mis­sion for In­ter­cept Phar­ma­ceu­ti­cals and Al­fasig­ma’s pri­ma­ry bil­iary cholan­gi­tis treat­ment Ocali­va af­ter safe­ty con­cerns dogged the prod­uct, cast­ing its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER